NEW YORK, NY / ACCESSWIRE / April 4, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Bristow Group Inc. (BRS)
Class Period: February 8, 2018 to February 12, 2019
Lead Plaintiff Deadline: April 15, 2019
The lawsuit alleges that Bristow Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Bristow lacked adequate monitoring processes related to non-financial covenants within its secured financing and lease agreements; (2) Bristow could not reasonably assure compliance with certain non-financial covenants; (3) Bristow was reasonably likely to breach certain agreements; (4) Bristow had understated its short-term debt; (5) the required corrections would materially impact financial statements; (6) there was a material weakness in Bristow's internal controls over financial reporting; and (7) as a result of the foregoing, defendants' positive statements about Bristow's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the BRS lawsuit: http://www.kleinstocklaw.com/pslra-1/bristow-group-inc-loss-submission-form?wire=3
Vanda Pharmaceuticals Inc. (VNDA)
Class Period: November 4, 2015 to February 11, 2019
Lead Plaintiff Deadline: April 26, 2019
During the class period, Vanda Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda's promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants' statements about Vanda's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the VNDA lawsuit: http://www.kleinstocklaw.com/pslra-1/vanda-pharmaceuticals-inc-loss-submission-form?wire=3
Inogen, Inc. (INGN)
Class Period: November 8, 2017 to February 26, 2019
Lead Plaintiff Deadline: May 6, 2019
Throughout the class period, Inogen, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Inogen had overstated the true size of the total addressable market (''TAM'') for its portable oxygen concentrators and had misstated the basis for its calculation of the TAM; (ii) Inogen had falsely attributed its sales growth to the strong sales acumen of its salesforce, when in reality it was due in large part to sales tactics designed to deceive its elderly customer base; (iii) the growth in Inogen's domestic business-to-business sales to home medical equipment (''HME'') providers was inflated, unsustainable and was eroding direct-to-consumer sales; and (iv) very little of Inogen's business was actually coming from the more stable Medicare market.
Get additional information about the INGN lawsuit: http://www.kleinstocklaw.com/pslra-1/inogen-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: